(Q37602525)

21 August 2017

1 reference

title

The nephrotoxic effects of HAART. (English)

1 reference

21 August 2017

Hassane Izzedine

1

1 reference

21 August 2017

Marianne Harris

series ordinal

2

1 reference

21 August 2017

Mark A Perazella

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Nature Reviews Nephrology

21 August 2017

1 reference

21 August 2017

5

1 reference

21 August 2017

10

1 reference

21 August 2017

563-573

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2009.142

21 August 2017

0 references

cites work

Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999--2003.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Factors associated with chronic renal failure in HIV-infected ambulatory patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

CD4+ count-guided interruption of antiretroviral treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Incidence and etiology of acute renal failure among ambulatory HIV-infected patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

HIV care and the incidence of acute renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Acute renal failure in an HIV-positive 50-year-old man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal safety of tenofovir in HIV treatment-experienced patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Fanconi's syndrome in HIV+ adults: report of three cases and literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Fanconi syndrome associated with didanosine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Effects of hypokalemia and hypomagnesemia on zidovudine (AZT) and didanosine (ddI) nephrotoxicity in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

31 March 2020

Efavirenz urolithiasis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Urolithiasis in HIV-positive patients treated with atazanavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Acute interstitial nephritis secondary to the administration of indinavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Atazanavir crystal nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Serological detection of attenuated HIV-1 variants with nef gene deletions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal atrophy associated with long-term treatment with indinavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Severe hypertension and renal atrophy associated with indinavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

HIV protease inhibitors acutely impair glucose-stimulated insulin release.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Crystal-induced acute renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Rosiglitazone reverses tenofovir-induced nephrotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Mechanism of active renal tubular efflux of tenofovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.142

Acute interstitial nephritis associated with atazanavir, a new protease inhibitor

31 March 2020

1 reference

12 December 2020

Nelfinavir urinary stones

1 reference

12 December 2020

Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys.

1 reference

12 December 2020

Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.

1 reference

12 December 2020

Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

1 reference

12 December 2020

Renal calculi developing de novo in a patient taking saquinavir

1 reference

12 December 2020

Drug-drug interactions that matter

1 reference

12 December 2020

Renal disease and toxicities: issues for HIV care providers

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2009.142

1 reference

21 August 2017

1 reference